5 Ways Market Research Accelerates Clinical Trial Enrollment

5 Ways Market Research Accelerates Clinical Trial EnrollmentMarket research accelerates clinical trial enrollment in many ways. Here are just five of them.

1. Determine why sites are not engaged in an ongoing study

All of the modeling and evaluation of screen failure data will not convey that a key third party vendor’s helpline makes coordinators wait on hold for 40 minutes, and when finally reached are not very helpful. Or, when there has been excessive turnover of CRAs.

Direct, anonymous input from study coordinators is the best way to identify site engagement issues hindering patient enrollment.

2. Improve outreach communications

Too often, outreach communications use words not understood by patients, images communicating the opposite of what was intended, and media that simply don’t work.

On the commercial side of the business, pharmaceutical companies use market research regularly to help frame messages and improve communications. This same tool should be used regularly by clinical operations to improve the communications to physicians, other healthcare providers and patients.

3. Refine protocol design

When designing a protocol for a unique indication or in a therapeutic area novel to the sponsor, input from investigators and coordinators who have experience with similar trials, but who are not being contacted by those who select sites, helps avoid pitfalls that hinder patient enrollment.

4. Direct patient input into Phase 3 protocols

Nothing says ‘patient-centric’ more than eliciting recommendations from patients who participated in your own Phase 2 studies. Patients, and family members, can tell you how they learned about a study, why they decided to participate, what questions/concerns they had, practical issues during the trial that could be improved, and what should be done to maximize retention.

5. When acquiring another company

When your company is acquiring another pharmaceutical company with compounds in development, you need to ensure that the investigators familiar with the acquired company will continue to produce after the acquisition.

Leave a Reply